Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16

Justin C. Yang1,2*, Andres Roman-Urrestarazu1*, Carol Brayne1

1 Cambridge Institute of Public Health, University of Cambridge, Cambridge, United Kingdom, 2 Department of Epidemiology and Applied Clinical Research, Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom

* These authors contributed equally to this work.
* justin.yang@ucl.ac.uk

Abstract

Objective
To identify the geographic, organisational, and payment correlates of buprenorphine and methadone treatment among substance abuse treatment (SAT) providers.

Methods
Secondary analyses of the National Survey of Substance Abuse Treatment Services (NSSATS) from 2007–16 were conducted. We provide bivariate descriptive statistics regarding substance abuse treatment services which offered buprenorphine and methadone treatment from 2007–16. Using multiple logistic regression, we regressed geographic, organisational, and payment correlates on buprenorphine and methadone treatment.

Results
Buprenorphine is increasingly offered at SAT facilities though uptake remains comparatively low outside of the northeast. SAT facilities run by tribal governments or Indian Health Service which offer buprenorphine remain low compared to privately operated SAT facilities (AOR = 0.528). The odds of offering buprenorphine among facilities offering free or no charge treatment (AOR = 0.838) or a sliding fee scale (AOR = 0.464) was lower. SAT facilities accepting Medicaid payments showed higher odds of offering methadone treatment (AOR = 2.035).
Conclusions
Greater attention towards the disparities in provision of opioid agonist therapies is warranted, especially towards the reasons why uptake has been moderate among civilian providers. Additionally, the care needs of Native Americans facing opioid-related use disorders bears further scrutiny.

Introduction
The ongoing and sustained opioid epidemic in the United States has manifested as one of the most urgent contemporary public health problems such that the United States Centers for Disease Control and Prevention (CDC) added the crisis to its list of the top five public health challenges in 2014 [1]. Opioid overdose deaths have increased at an alarming and accelerated rate; from 2015–16, for instance, deaths due to opioid overdose increased 27.7% [2]. Opioid overdose mortality and its associated economic burden have been among the major consequences of this epidemic; in 2014, for instance, 61% of drug overdose deaths involved opioids [3] while health care spending among individuals with opioid abuse averages eight times higher than individuals without opioid abuse [4].

The burden of the opioid epidemic, involving both the misuse of prescribed opioids and the use of illicit opioids, has not manifested uniformly across the United States. One study found that drug poisoning mortality and opioid consumption rates varied significantly by state and region with drug poisoning rates highest in the Southwest and lowest in the Midwest [5]. Moreover, sales of opioid analgesics, which are prone to abuse, have varied significantly by state as well, with Alaska showing a 13 times higher methadone distribution than Nebraska in 2002 [5]. Another study has found that prescription drug abuse of oxycodone has been unevenly concentrated in eastern and southeastern states with a pattern of migration from the northeast and Appalachia towards the southeast and west [6].

Despite the self-evident need for effective opioid misuse treatment, systemic barriers to treatment persist [7, 8], particularly with respect to the type and mode of treatment [9, 10]. Because of the strict Federal regulatory oversight of pharmacotherapies for the treatment of opioid misuse, the accessibility or lack thereof of treatments such as buprenorphine and methadone has come under heightened scrutiny by researchers and practitioners [11] despite the fact that the American Psychiatric Association (APA) has endorsed the use of pharmacotherapy combined with psychotherapy as best practice [12, 13] and the American Society of Addiction Medicine (ASAM) has established the use pharmacotherapy for the treatment of opioid use disorder as a practice guideline [14]. Indeed, some practitioners have called for increased access to buprenorphine in the outpatient setting [15]. In addition, as broader patterns of macroeconomy have experienced a downturn at the start of the millennium, substance abuse treatment providers have responded with respect to changes to patient mix by changes in provider operators and acceptance of private health insurance [16].

In this study, we make use of a routine, annual survey of all substance abuse treatment (SAT) facilities in the United States to characterise the ways in which pharmacotherapeutic approaches to managing opioid use disorders, specifically buprenorphine and methadone, have or have not varied during ten recent years of the opioid epidemic from 2007–16, based on geographic, operational, and payment characteristics. By doing so, we seek to describe ongoing trends in SAT facility operations and whether or not disparities exist based on geographic, operational, and payment characteristics with respect to buprenorphine and

Competing interests: The authors have declared that no competing interests exist.
methadone treatment, particularly given the clinical evidence supporting their use in opioid abuse treatment [17]. Finally, we provide some recommendations for policymakers to address issues facing the treatment of opioid use disorders based on our findings.

Methods

Our study used data from the 2007–16 waves of the National Survey of Substance Abuse Treatment Services (N-SSATS), an annually repeated, survey of all known drug and alcohol abuse treatment facilities, both public and private, in the United States [18–27]. Given that the N-SSATS is a point-prevalence survey, where data is collected over a short, defined period of time in contrast to a longitudinal study, facilities are surveyed year after year [18–27]. The number of responses vary by year, with a minimum of 13,066 and a maximum of 14,162. The average number of responses per year was 13,614. In our analysis, we make use of 136,143 responses from 2007–16. The N-SSATS collects data regarding the location and characteristics of each substance abuse treatment (SAT) facility as well as the types of services offered [18–27]. Data is collected through mailed questionnaires, telephone interviews, and web-based surveys [18–27]. No adjustment is made for the approximately 5–10% facility nonresponse [18–27].

N-SSATS respondent location was categorized using Census Bureau Divisions (“division”) [28]: New England; Mid-Atlantic; East North Central; West North Central; South Atlantic; East South Central; West South Central; Mountain; and Pacific. SAT facility operating entities were defined as one of: private for-profit; private non-profit; state government; local government; tribal government; Department of Veterans Affairs (VA); Department of Defense (DoD); Indian Health Service (IHS); or other Federal agency [18–27]. SAT facility payment characteristics were also obtained from the N-SSATS. Dichotomous variables were coded to indicate whether a SAT facility provided no charge or free treatment, offered a sliding fee scale to patients, accepted cash payments, accepted private insurance, accepted Medicare, accepted Medicaid, accepted state (non-Medicaid) insurance, and accepted federal Military insurance [18–27].

Our outcome variables of interest were dichotomous variables coded to indicate whether a SAT facility offered specific pharmacotherapies: buprenorphine (with or without naltrexone) and methadone [18–27]. For our analyses of SAT facilities offering methadone, only facilities indicating the presence of an opioid treatment program (OTP) were assessed, as methadone dispensing is strictly regulated by Federal regulations and limited to OTPs [29].

All statistical analyses were performed in Stata 14 [30]. Bivariate descriptive analyses were conducted for our outcome variables of interest regarding service types and pharmacotherapies compared to facility characteristics, including geography, operating entity, and payment characteristics as detailed above. Multiple maximum-likelihood logit regressions weighted least squares were performed on these outcome variables, with and without adjustment, to yield odds ratios associated with SAT facility characteristics, specifically, geography, operating entity, and payment characteristics. The baseline characteristics used for logistic regressions were: New England for division, private for-profit for operating entity, and the counterfactual condition for payment characteristics (e.g. the counterfactual for “offers free or no charge treatment” would be “does not offer free or no charge treatment”). In addition to adjustment for our covariates of interest, all regression models also adjusted for year.

Results

Descriptive characteristics for our study population are shown in Table 1.
As shown in Fig 1, the number of SAT facilities generally increased from 2007–16 across divisions except for Pacific where a decline in the number of SAT facilities from 2008 is observed. SAT facilities across all regions were mostly operated by private entities from 2007–16, ranging from 86.5% of all surveyed SAT facilities in 2007 to 88.6% in 2016.

The percentage of SAT facilities offering buprenorphine increased from 2007–16 ($\chi^2$, nearly doubling from 14.4% of all SAT facilities to 27.2%, across all divisions as shown in Fig 2; nevertheless, less than half of SAT facilities in New England and Mid-Atlantic, and South Atlantic offered buprenorphine in 2016 and less than 25% did so in other divisions. Also shown in Fig 2, the percentage of SAT facilities buprenorphine increased from 2007–16 among SAT facilities whose operating entities were private-for-profit, private non-profit, state government, and

### Table 1. Characteristics of study population, 2007–16.

| Year | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  | 2014  | 2015  | 2016  |
|------|------|------|------|------|------|------|------|------|------|------|
| n    | 13352| 13404| 13233| 13066| 13462| 14056| 13873| 13914| 13621| 14162|
| Census Division |        |      |      |      |      |      |      |      |      |      |
| New England | 6.4% | 6.5% | 6.3% | 6.3% | 6.5% | 6.7% | 6.5% | 6.6% | 6.5% | 6.8% |
| Mid-Atlantic | 13.4%| 13.7%| 13.8%| 14.2%| 13.9%| 13.2%| 13.0%| 13.2%| 13.2%| 12.8%|
| East North Central | 15.8%| 15.5%| 15.3%| 15.0%| 15.1%| 14.9%| 15.1%| 15.1%| 14.9%| 14.8%|
| West North Central | 8.4% | 8.3% | 8.2% | 8.6% | 8.8% | 8.8% | 8.6% | 8.9% | 9.0% | 9.0% |
| South Atlantic | 15.6%| 16.0%| 16.0%| 15.5%| 15.8%| 16.0%| 16.4%| 16.7%| 17.0%| 17.2%|
| East South Central | 5.6% | 5.4% | 5.4% | 5.6% | 5.7% | 5.9% | 5.8% | 5.7% | 5.8% | 5.8% |
| West South Central | 6.8% | 6.6% | 6.6% | 6.6% | 6.5% | 6.7% | 6.8% | 6.7% | 6.5% | 6.8% |
| Mountain | 8.6% | 8.9% | 8.8% | 9.3% | 9.2% | 9.9% | 10.1%| 10.0%| 10.3%| 10.4%|
| Pacific | 19.4%| 19.1%| 19.6%| 18.9%| 18.6%| 17.9%| 17.6%| 17.1%| 16.8%| 16.4%|
| Operating Entity |        |      |      |      |      |      |      |      |      |      |
| Private-for-Profit | 28.5%| 29.3%| 29.3%| 30.0%| 30.6%| 31.1%| 32.3%| 33.0%| 33.6%| 35.4%|
| Private Non-Profit | 58.0%| 58.0%| 57.9%| 57.5%| 57.3%| 56.3%| 55.3%| 55.2%| 54.6%| 53.2%|
| State Government | 3.1% | 3.0% | 2.9% | 2.7% | 2.4% | 2.4% | 2.3% | 2.3% | 2.4% | 2.2% |
| Local, County, or Community Government | 6.6% | 6.1% | 6.0% | 5.7% | 5.5% | 5.4% | 5.3% | 5.1% | 5.1% | 5.0% |
| Tribal Government | 1.4% | 1.3% | 1.4% | 1.4% | 1.6% | 2.3% | 2.1% | 2.0% | 1.9% | 1.8% |
| Department of Veterans Affairs | 1.4% | 1.3% | 1.6% | 1.7% | 1.7% | 1.5% | 1.6% | 1.5% | 1.5% | 1.5% |
| Department of Defense | 0.7% | 0.7% | 0.7% | 0.7% | 0.7% | 0.6% | 0.6% | 0.6% | 0.6% | 0.6% |
| Indian Health Service | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.4% | 0.3% | 0.2% | 0.2% | 0.2% |
| Other Federal Government Agency | 0.1% | <0.05% | <0.05% | <0.05% | <0.05% | <0.05% | 0.1% | 0.1% | 0.1% | <0.05% |
| Facility Characteristic |        |      |      |      |      |      |      |      |      |      |
| Operate an Opioid Treatment Program | 8.3% | 99.7%| 99.7%| 8.8% | 8.8% | 8.2% | 9.2% | 9.4% | 9.8% | 9.2% |
| Types of Payment Assistance Offered |        |      |      |      |      |      |      |      |      |      |
| Offers no charge or free treatment | 52.6%| 52.1%| 51.5%| 49.6%| 49.3%| 49.5%| 48.3%| 47.1%| 46.6%| 45.5%|
| Sliding fee scale | 62.8%| 62.9%| 62.8%| 62.7%| 62.7%| 62.2%| 62.4%| 61.4%| 60.6%| 59.6%|
| Accepted Payment Types |        |      |      |      |      |      |      |      |      |      |
| Cash or Self-Payment | 91.3%| 90.1%| 91.1%| 91.5%| 91.6%| 90.7%| 91.3%| 90.8%| 90.5%| 90.4%|
| Private Health Insurance | 66.1%| 64.7%| 64.8%| 65.8%| 66.2%| 66.8%| 67.3%| 68.7%| 69.4%| 70.5%|
| Medicare | 35.8%| 35.9%| 34.2%| 33.9%| 34.1%| 34.6%| 34.6%| 34.6%| 35.1%| 35.6%|
| Medicaid | 56.0%| 55.5%| 56.0%| 57.0%| 58.8%| 60.3%| 61.0%| 62.1%| 63.6%| 63.8%|
| State-Financed Health Insurance | 37.5%| 41.3%| 41.1%| 42.0%| 42.0%| 43.4%| 44.4%| 47.4%| 48.4%| 49.2%|
| Federal Military Insurance | 35.7%| 35.4%| 35.6%| 35.5%| 36.0%| 36.5%| 35.9%| 36.7%| 36.1%| 36.5%|
| Pharmacotherapies Offered |        |      |      |      |      |      |      |      |      |      |
| Buprenorphine (with or without naloxone) | 14.4%| 15.2%| 17.2%| 18.6%| 19.9%| 20.7%| 22.2%| 23.4%| 24.8%| 27.2%|
| Methadone | 11.2%| 8.4% | 11.4%| 11.5%| 11.3%| 11.3%| 11.7%| 11.8%| 12.1%| 12.5%|

As shown in Fig 1, the number of SAT facilities generally increased from 2007–16 across divisions except for Pacific where a decline in the number of SAT facilities from 2008 is observed. SAT facilities across all regions were mostly operated by private entities from 2007–16, ranging from 86.5% of all surveyed SAT facilities in 2007 to 88.6% in 2016. The percentage of SAT facilities offering buprenorphine increased from 2007–16 ($\chi^2$, nearly doubling from 14.4% of all SAT facilities to 27.2%, across all divisions as shown in Fig 2; nevertheless, less than half of SAT facilities in New England and Mid-Atlantic, and South Atlantic offered buprenorphine in 2016 and less than 25% did so in other divisions. Also shown in Fig 2, the percentage of SAT facilities buprenorphine increased from 2007–16 among SAT facilities whose operating entities were private-for-profit, private non-profit, state government, and
Fig 1. Number of SAT Facilities by Census Bureau Division, 2007–16, and Percentage of SAT Facilities by Operating Entity by Census Bureau Division, 2007–16.

https://doi.org/10.1371/journal.pone.0229787.g001

Fig 2. Percentage of SAT Facilities Offering Buprenorphine by Census Bureau Division, 2007–16, and Percentage of SAT Facilities Offering Buprenorphine by Operating Entity, 2007–16.

https://doi.org/10.1371/journal.pone.0229787.g002
VA, markedly so in the latter case where buprenorphine was offered at approximately three-quarters of SAT facilities operated by the VA in 2016. By contrast, less than 25% of SAT facilities operated by tribal governments, DoD or IHS offered buprenorphine from 2007–16.

Overall, the number of SAT facilities which operated an OTP remained stable from 2007–16, just below 10%. The number of SAT facilities which ran an OTP increased in South Atlantic and remained relatively constant in most other divisions as shown in Fig 3. In Mid-Atlantic, we observed an increase in the number of SAT facilities running an OTP in 2008, then declining until 2012 before increase again through to 2015. Reflecting broader patterns in facility operation noted above, SAT facilities running an OTP were predominantly operated by private entities.

Table 2 shows the results of unadjusted and adjusted results of logistic regression of geographic, operational, and payment characteristics associated with whether SAT facilities offered buprenorphine and methadone pharmacotherapies from 2007–16. These results are also shown graphically in Figs 4 and 5. SAT facilities in most divisions, except for Mid-Atlantic (AOR: 1.15; 95% CI: 1.08–1.22), showed lower odds of offering buprenorphine treatment when compared to New England. SAT facilities operated by private non-profit entities (AOR: 0.85; 95% CI: 0.82–0.88), local, county, or community governments (AOR: 0.71; 95% CI: 0.66–0.77), tribal governments (AOR: 0.53; 95% CI: 0.45–0.62), or IHS (AOR: 0.65; 95% CI: 0.45–0.95) showed lower odds of offering buprenorphine while those operated by state government (AOR: 1.22; 95% CI: 1.11–1.35) or VA (AOR: 9.58; 95% CI: 8.40–10.93) showed higher odds of offering buprenorphine. SAT facilities accepting any type of payment assistance, either charity care or a sliding fee scale, showed lower odds of offering buprenorphine than those that did not offer any form of payment assistance. SAT facilities accepting cash or self-payment (AOR: 2.09; 95% CI: 1.94–2.25), private health insurance (AOR: 2.01; 95% CI: 1.93–2.25), Medicare

Fig 3. Number of SAT Facilities with OTPs by Census Bureau Division, 2007–16, and Percentage of SAT Facilities with OTPs Offering Methadone by Census Bureau Division, 2007–16.

https://doi.org/10.1371/journal.pone.0229787.g003
For methadone treatment, different trends among geographic, operational, and payment characteristics were found among SAT facilities operating an OTP. Compared to SAT facilities in New England, SAT facilities in Pacific showed higher odds of offering methadone treatment (AOR: 6.40; 95% CI: 2.93–13.98). Of the SAT facilities which responded to the N-SSATS from 2007–16, no SAT facilities operated by DoD ran an OTP and no SAT facilities operated by IHS or another Federal government agency offered methadone treatment. SAT facilities operated by a private non-profit entity (AOR: 0.57; 95% CI: 0.40–0.83) or by tribal government (AOR: <0.01) showed lower odds of offering methadone treatment than SAT facilities operated by a private-for-profit entity, particularly so in the latter case. SAT facilities accepting private health

Table 2. Unadjusted and adjusted multiple logistic regression of SAT facility characteristics associated with pharmacotherapies offered.

| Census Bureau Division | Buprenorphine | Methadone* | Buprenorphine | Methadone* |
|------------------------|---------------|------------|---------------|------------|
|                        | Unadjusted Odds Ratios | Adjusted Odds Ratios *** | Unadjusted Odds Ratios | Adjusted Odds Ratios *** |
| New England            | 1              | 1          | 1             | 1          |
| Mid-Atlantic           | 1.051 (0.994–1.110) | 1.147 (1.076–1.222) | 0.981 (0.713–1.350) | 0.621 (0.424–0.911) |
| East North Central     | 0.524 (0.494–0.555) | 0.466 (0.437–0.498) | 1.730 (1.132–2.642) | 1.144 (0.702–1.864) |
| West North Central     | 0.336 (0.313–0.361) | 0.278 (0.256–0.301) | 2.993 (1.284–6.979) | 3.979 (1.383–11.44) |
| South Atlantic         | 0.755 (0.715–0.797) | 0.750 (0.704–0.799) | 1.821 (1.266–2.621) | 0.908 (0.583–1.415) |
| East South Central     | 0.354 (0.327–0.384) | 0.320 (0.292–0.350) | 2.566 (1.164–5.657) | 0.882 (0.354–2.199) |
| West South Central     | 0.453 (0.421–0.486) | 0.452 (0.416–0.491) | 5.744 (2.614–12.62) | 2.772 (0.999–7.692) |
| Mountain               | 0.551 (0.518–0.587) | 0.559 (0.521–0.601) | 2.298 (1.275–4.140) | 1.661 (0.791–3.488) |
| Pacific                | 0.418 (0.395–0.442) | 0.512 (0.479–0.548) | 5.209 (2.945–9.214) | 6.400 (2.929–13.98) |

| Operating Entity       | Buprenorphine | Methadone* | Buprenorphine | Methadone* |
|------------------------|---------------|------------|---------------|------------|
|                        | Unadjusted Odds Ratios | Adjusted Odds Ratios *** | Unadjusted Odds Ratios | Adjusted Odds Ratios *** |
| Private-for-Profit     | 1              | 1          | 1             | 1          |
| Private Non-Profit     | 0.704 (0.684–0.725) | 0.849 (0.818–0.881) | 0.292 (0.225–0.380) | 0.574 (0.398–0.826) |
| State Government       | 0.954 (0.879–1.035) | 1.223 (1.110–1.348) | 0.322 (0.165–0.628) | 0.475 (0.224–1.008) |
| Local, County, or Community Government | 0.588 (0.550–0.628) | 0.714 (0.660–0.772) | 0.480 (0.260–0.885) | 1.260 (0.542–2.928) |
| Tribal Government      | 0.374 (0.327–0.427) | 0.528 (0.449–0.622) | 0.0549 (0.0258–0.117) | 0.00860 (0.00301–0.0246) |
| Department of Veterans Affairs | 6.412 (5.836–7.045) | 9.583 (8.403–10.93) | 0.195 (0.121–0.313) | 0.905 (0.432–1.893) |
| Department of Defense  | 0.466 (0.382–0.569) | 1.319 (1.059–1.642) | **              | **          |
| Indian Health Service  | 0.350 (0.249–0.492) | 0.653 (0.450–0.947) | **              | **          |
| Other Federal Government Agency | 0.950 (0.523–1.726) | 1.290 (0.661–2.519) | **              | **          |

| Types of Payment Assistance Offered | Buprenorphine | Methadone* | Buprenorphine | Methadone* |
|------------------------------------|---------------|------------|---------------|------------|
| Offers no charge or free Tx        | 0.684 (0.666–0.702) | 0.838 (0.809–0.867) | 0.514 (0.411–0.643) | 1.004 (0.740–1.360) |
| Uses sliding fee scale             | 0.568 (0.553–0.583) | 0.464 (0.448–0.480) | 0.674 (0.538–0.844) | 0.994 (0.731–1.351) |

| Accepted Payment Types             | Buprenorphine | Methadone* | Buprenorphine | Methadone* |
|------------------------------------|---------------|------------|---------------|------------|
| Accepts cash or self-payment       | 1.838 (1.740–1.942) | 2.085 (1.936–2.245) | 1.838 (1.081–3.125) | 2.009 (1.027–3.931) |
| Accepts private health insurance   | 2.269 (2.197–2.343) | 2.012 (1.930–2.097) | 0.114 (0.0791–0.165) | 0.157 (0.101–0.245) |
| Accepts Medicare payments          | 1.646 (1.602–1.691) | 1.458 (1.402–1.515) | 0.304 (0.242–0.381) | 0.696 (0.510–0.950) |
| Accepts Medicaid payments          | 1.291 (1.256–1.327) | 1.088 (1.045–1.132) | 0.521 (0.396–0.686) | 2.035 (1.372–3.017) |
| Accepts state-financed health insurance | 1.303 (1.268–1.339) | 0.977 (0.941–1.015) | 0.313 (0.246–0.398) | 0.767 (0.557–1.055) |
| Accepts Federal military insurance | 1.540 (1.497–1.583) | 0.953 (0.917–0.990) | 0.232 (0.183–0.294) | 0.575 (0.426–0.776) |

* Logistic regression was run only for facilities indicating a registered OTP
** No facilities operated by DoD, IHS, another Federal government agency indicated they registered OTP
*** Adjusted for year, geography, operating entity, and payment characteristics

(AOR: 1.46; 95% CI: 1.40–1.52), or Medicaid (AOR: 1.09; 95% CI: 1.05–1.13) all showed higher odds of offering buprenorphine than those not accepting.

For methadone treatment, different trends among geographic, operational, and payment characteristics were found among SAT facilities operating an OTP. Compared to SAT facilities in New England, SAT facilities in Pacific showed higher odds of offering methadone treatment (AOR: 6.40; 95% CI: 2.93–13.98). Of the SAT facilities which responded to the N-SSATS from 2007–16, no SAT facilities operated by DoD ran an OTP and no SAT facilities operated by IHS or another Federal government agency offered methadone treatment. SAT facilities operated by a private non-profit entity (AOR: 0.57; 95% CI: 0.40–0.83) or by tribal government (AOR: <0.01) showed lower odds of offering methadone treatment than SAT facilities operated by a private-for-profit entity, particularly so in the latter case. SAT facilities accepting private health
insurance (AOR: 0.16; 95% CI: 0.10–0.25) and Medicare (AOR: 0.70; 95% CI: 0.51–0.95) showed lower odds of offering methadone treatment than those that did not accept those forms of payment while SAT facilities accepting Medicaid showed double the odds of offering methadone treatment than SAT facilities not accepting Medicaid (AOR: 2.04; 95% CI: 1.37–3.02).

Discussion

Our results showed changes in the SAT facility landscape from 2007–16 and highlighted differences in buprenorphine and methadone treatment availability based upon geographic, operational, and payment characteristics. Firstly, though it is promising to see that buprenorphine is increasingly offered at SAT facilities among all divisions, uptake remained low outside of the northeast; we observe that all regions, except for Mid-Atlantic, showed lower odds of SAT facilities offering buprenorphine treatment. Moreover, though SAT facilities across a range of operational entities increasingly offered buprenorphine treatment, the percentage of SAT facilities run by tribal governments or IHS which offered buprenorphine remains low, highlighting a potential disparity in treating Native Americans. Though SAT facilities operated by the VA which offer buprenorphine have rapidly increased, growth has been more attenuated among facilities run by other operational entities as shown by the odds of SAT facilities offering buprenorphine among these SAT facilities. The odds of offering buprenorphine among facilities offering payment assistance was lower than those without payment assistance. For methadone, on the other hand, we observed that SAT facilities accepting Medicaid payments showed higher odds of offering methadone treatment.
Our analyses are limited by the shortcomings of data drawn from the N-SSATS. Given major changes to survey design in 2007, namely the exclusion of questions capturing our independent and dependent variables of interest, inclusion of prior waves of the N-SSATS which could have extended our study period was not possible. Moreover, the N-SSATS does not collect information regarding client mix among SAT facilities. As client mix and needs contribute to the determination of individual SAT facility service offerings, this omission may have contributed to omitted variables bias. Nevertheless, given that the N-SSATS is intended to be a comprehensive annual survey of all SAT facilities in the United States, our analysis is strengthened as we can analyse nearly all SAT facilities rather than relying on a generalizable sample [18–27]. Our use of a ten-year long study period further contributes to our attempts to mitigate bias. In addition, to our knowledge, no other dataset currently exists which documents SAT facilities on a national level to the extent that the N-SSATS provides.

Given the magnitude of the opioid epidemic and its sustained impact on population health, our findings suggest that greater attention towards the provision of pharmacotherapies for the treatment of opioid-related use disorders is warranted, such as understanding the reasons why uptake of pharmacotherapies for the treatment of opioid-related use disorders has been moderate among civilian healthcare providers. This can complement ongoing and sustained efforts to alter prescribing practices [31] and to generate novel formulations of abuse-deterrent opioid analgesics [32]. The relatively low numbers of civilian SAT facilities reporting the availability of buprenorphine therapy is concerning, given research which suggests that drug-free treatments may contribute towards greater patient mortality than medication-assisted therapy [33]. Though buprenorphine prescription has, to date, been strictly limited by law, researchers have called on lawmakers to consider relaxing such restrictions as they may contribute to greater...
patient harm [34]. Previous research has found a similar trend regarding the supply of waived physicians in the northeast relative to other regions [35] and though some have offered explanations for this with respect to health care reform [36] or regional variations in opioid mortality [37], more research is needed to better understand the factors which have led to the relatively low uptake of buprenorphine treatment outside of the northeast. A number of general causes have been suggested as contributory towards the relatively low use of buprenorphine treatment, including a shortage of certified prescribers and worries about patient diversion [38, 39] as well as insufficient prescriber knowledge about the use of opioid agonist therapy and potential stigma associated with its use [40].

Our findings are consistent with other analyses of pharmacotherapy among providers primarily focused on Native Americans which have also identified low rates of pharmacotherapy implementation for substance abuse treatment [41]. In the case of opioids specifically, some qualitative research suggests that the high prevalence of oxycodone use among a tribal community has led to heightened sensitivity regarding opioid misuse [42], suggesting that approaches to increasing the use of pharmacotherapy for opioid-related substance use disorders must be culturally appropriate and contextual to the needs of Native Americans [43]. Developing cultural competence and capacity for evidence-based treatment of opioid-related substance disorders will contribute greatly to addressing the disparities we have identified.

With respect to methadone treatment, the relatively static number of SAT facilities with OTPs over time may be cause for concern as the number of individuals with opioid-related use disorders continues to increase. One study assessing the gap between treatment need and capacity for OTPs found that 96% of states showed opioid abuse or dependence rates higher than their OTP capacity rates with 38 states reporting at least 75% of their OTPs were operating at 80% capacity or more [11]. One way of addressing the lack of growth of OTPs is by devoting greater resources towards expanding the number of waivered physicians who can provide buprenorphine in the physician office setting, particularly among rural areas which have been underserved with respect to opioid-related substance disorder treatment [44]. Another approach is to relax the patient limits set on waivered physicians which can be a less resource-intensive method of increasing capacity for care without the need to increasing the number of SAT facilities, OTP programs, or waivered physicians [45].

Opioid use disorder continues to present pressing and urgent challenges to public health. SAT facilities, which serve a crucial role in the treatment of opioid use disorder, have generally shown an increase in the use of buprenorphine yet this increase was not observed as strongly among facilities offering payment assistance, a characteristic which may determine patient access to treatment. Nevertheless, our observation that facilities accepting Medicaid payments showed higher odds of offering methadone treatment suggests that there may be other opportunities where low-income, uninsured, or underinsured patients may receive medicated-assistant treatment. Still, much more research is needed to understand how SAT facilities as a whole, whether by policy or in practice, have responded to the opioid crisis. More nuanced approaches to understanding local and regional contexts for opioid use disorders and their treatment will enable more responsive care planning and service provision where it is needed most, for instance, among areas with high populations of Native Americans.

**Author Contributions**

**Conceptualization:** Justin C. Yang, Andres Roman-Urrestarazu, Carol Brayne.

**Data curation:** Justin C. Yang.

**Formal analysis:** Justin C. Yang.
Investigation: Justin C. Yang.

Methodology: Justin C. Yang, Andres Roman-Urrestarazu.

Project administration: Andres Roman-Urrestarazu, Carol Brayne.

Software: Justin C. Yang.

Supervision: Andres Roman-Urrestarazu, Carol Brayne.

Validation: Justin C. Yang.

Visualization: Justin C. Yang.

Writing – original draft: Justin C. Yang.

Writing – review & editing: Andres Roman-Urrestarazu, Carol Brayne.

References

1. Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annual review of public health. 2015; 36:559–74. Epub 2015/01/13. https://doi.org/10.1146/annurev-publhealth-031914-122957 PMID: 25581144.

2. Vivolo-Kantor AM, Seth P, Gladden RM, Mattson CL, Baldwin GT, Kite-Powell A, et al. Vital signs: trends in emergency department visits for suspected opioid overdoses—United States, July 2016–September 2017. Morbidity and Mortality Weekly Report. 2018; 67(9):279. https://doi.org/10.15585/mmwr.mm6709e1 PMID: 29518069.

3. Rudd RA. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morbidity and mortality weekly report. 2016; 65.

4. Meyer R, Patel AM, Rattana SK, Quock TP, Mody SH. Prescription opioid abuse: a literature review of the clinical and economic burden in the United States. Popul Health Manag. 2014; 17(6):372–87. Epub 2014/07/31. https://doi.org/10.1089/pop.2013.0098 PMID: 25075734; PubMed Central PMID: PMC4273187.

5. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. 2006; 31(6):506–11.

6. Cicero TJ, Inciardi JA, Muñoz AJ. Trends in abuse of OxyContin® and other opioid analgesics in the United States: 2002–2004. 2005; 6(10):662–72.

7. Chen LY, Strain EC, Crum RM, Mojtabai R. Gender differences in substance abuse treatment and barriers to care among persons with substance use disorders with and without comorbid major depression. J Addict Med. 2013; 7(5):325–34. Epub 2013/10/05. https://doi.org/10.1097/ADM.0b013e31829b7afe PMID: 24091763; PubMed Central PMID: PMC3791308.

8. Choi NG, Dinittio DM, Marti CN. Treatment use, perceived need, and barriers to seeking treatment for substance abuse and mental health problems among older adults compared to younger adults. Drug Alcohol Depend. 2014; 145:113–20. Epub 2014/12/03. https://doi.org/10.1016/j.drugalcdep.2014.10.004 PMID: 25456572.

9. Quinn PD, Hur K, Chang Z, Krebs EE, Bair MJ, Scott EL, et al. Incident and long-term opioid therapy among patients with psychiatric conditions and medications: a national study of commercial health care claims. Pain. 2017; 158(1):140–8. Epub 2016/12/17. https://doi.org/10.1097/j.pain.0000000000000730 PMID: 27984526; PubMed Central PMID: PMC5171228.

10. Short VL, Hand DJ, MacAfee L, Abatemarco DJ, Terplan M. Trends and disparities in receipt of pharmacotherapy among pregnant women in publicly funded treatment programs for opioid use disorder in the United States. J Subst Abuse Treat. 2018; 89:67–74. Epub 2018/05/01. https://doi.org/10.1016/j.jsat.2018.04.003 PMID: 29706175.

11. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health. 2015; 105(8):e55–63. Epub 2015/06/13. https://doi.org/10.2105/AJPH.2015.302664 PMID: 26066931; PubMed Central PMID: PMC4504312.

12. Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, et al. Medication-Assisted Treatment With Buprenorphine: Assessing the Evidence. Psychiatric Services. 2014; 65(2):158–70. https://doi.org/10.1176/appi.ps.201300256 PMID: 24247147.
13. Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, et al. Medication-Assisted Treatment With Methadone: Assessing the Evidence. Psychiatric Services. 2014; 65(2):146–57. https://doi.org/10.1176/appi.ps.201300235 PMID: 24248468

14. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Journal of Addiction Medicine. 2015; 9(5):358–67. https://doi.org/10.1097/ADM.0000000000000166 PMC4605275. PMID: 26406300

15. Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend. 2012; 126(3):379–83. Epub 2012/06/19. https://doi.org/10.1016/j.drugalcdepl.2012.05.025 PMID: 22704124; PubMed Central PMCID: PMC3449053.

16. Cantor J, Stoller KB, Saloner B. The response of substance use disorder treatment providers to changes in macroeconomic conditions. J Subst Abuse Treat. 2017; 81:59–65. Epub 2017/08/30. https://doi.org/10.1016/j.jsat.2017.07.005 PMID: 28847456.

17. Brady KT, McCaulley JL, Back SE. Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update. Am J Psychiatry. 2016; 173(1):18–26. Epub 2015/09/05. https://doi.org/10.1176/appi.ajp.2015.15020262 PMID: 26337039; PubMed Central PMCID: PMC4782928.

18. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey of Substance Abuse Treatment Services (NSSATS), 2007. Ann Arbor, MI: Inter-university Consortium for Political and Social Research, 2007.

19. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey of Substance Abuse Treatment Services (NSSATS), 2008. Ann Arbor, MI: Inter-university Consortium for Political and Social Research, 2008.

20. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey of Substance Abuse Treatment Services (NSSATS), 2009. Ann Arbor, MI: Inter-university Consortium for Political and Social Research, 2009.

21. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey of Substance Abuse Treatment Services (NSSATS), 2010. Ann Arbor, MI: Inter-university Consortium for Political and Social Research, 2010.

22. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey of Substance Abuse Treatment Services (NSSATS), 2011. Ann Arbor, MI: Inter-university Consortium for Political and Social Research, 2011.

23. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey of Substance Abuse Treatment Services (NSSATS), 2012. Ann Arbor, MI: Inter-university Consortium for Political and Social Research, 2012.

24. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey of Substance Abuse Treatment Services (NSSATS), 2013. Ann Arbor, MI: Inter-university Consortium for Political and Social Research, 2013.

25. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey of Substance Abuse Treatment Services (NSSATS), 2014. Ann Arbor, MI: Inter-university Consortium for Political and Social Research, 2014.

26. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey of Substance Abuse Treatment Services (NSSATS), 2015. Ann Arbor, MI: Inter-university Consortium for Political and Social Research, 2015.

27. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey of Substance Abuse Treatment Services (NSSATS), 2016. Ann Arbor, MI: Inter-university Consortium for Political and Social Research, 2016.

28. U.S. Department of Commerce Economics and Statistics Administration U.S. Census Bureau. Census Regions and Divisions of the United States.

29. Kresina TF, Litwin A, Marion I, Lubran R, Clark HWJJoDPA. United States government oversight and regulation of medication assisted treatment for the treatment of opioid dependence. 2009; 2(1).
30. Stata Statistical Software. Release 14 [computer program]. 2013.

31. Vadivelu N, Kai AM, Kodumudi G, Haddad D, Kodumudi V, Kuruvilla N, et al. Recommendations for Substance Abuse and Pain Control in Patients with Chronic Pain. Current pain and headache reports. 2018; 22(4):25. Epub 2018/03/21. https://doi.org/10.1007/s11916-018-0679-3 PMID: 29556830.

32. Pergolizzi JV Jr., Taylor R Jr., LeQuang JA, Raffa RB. Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product. J Pain Res. 2018; 11:301–11. Epub 2018/02/16. https://doi.org/10.2147/JPR.S127602 PMID: 29445297; PubMed Central PMCID: PMC5810535.

33. Clark RE, Sammaliev M, Baxter JD, Leung GY. The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Affairs. 2011; 30(8):1425–33. https://doi.org/10.1377/hlthaff.2010.0532 PMID: 21821560

34. Blum K, Gold M, Clark HW, Dushaj K, Badgaiyan RD. Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment? Substance Use & Misuse. 2016; 51(12):1674–9. https://doi.org/10.1080/10826084.2016.1200097 PMID: 29445297; PubMed Central PMCID: PMC5810535.

35. Knudsen HK. The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis. Journal of Studies on Alcohol and Drugs. 2015; 76(4):644–54. https://doi.org/10.15288/jsad.2015.76.644 PMID: 26098042

36. Knudsen HK, Lofwall MR, Havens JR, Walsh SL. States’ implementation of the Affordable Care Act and the supply of physicians waived to prescribe buprenorphine for opioid dependence. Drug and Alcohol Dependence. 2015; 157:36–43. https://doi.org/10.1016/j.drugalcdep.2015.09.032 PMID: 26483356

37. Knudsen HK, Havens JR, Lofwall MR, Studts JL, Walsh SL. Buprenorphine physician supply: Relationship with state-level prescription opioid mortality. Drug and Alcohol Dependence. 2017; 173:S55–S64. https://doi.org/10.1016/j.drugalcdep.2016.08.642 PMID: 28363321

38. Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? Journal of Substance Abuse Treatment. 2017; 78:1–7. https://doi.org/10.1016/j.jsat.2017.04.005 PMID: 28554597

39. Duncan LG, Mendoza S, Hansen H. Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers. J Addict Med Ther Sci. 2015; 1(2):31–6. Epub 2015/08/03. https://doi.org/10.17352/jms.2015.000008 PMID: 27088135.

40. Rieckmann TR, Kovas AE, McFarland BH, Abraham AJ. A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment. Journal of Substance Abuse Treatment. 2011; 41(4):374–85. https://doi.org/10.1016/j.jsat.2011.05.005 PMID: 21821379

41. Rieckmann T, Moore L, Croy C, Aarons GA, Novins DK. National Overview of Medication-Assisted Treatment for American Indians and Alaska Natives With Substance Use Disorders. Psychiatric Services. 2017; 68(11):1136–43. https://doi.org/10.1176/appi.ps.201600397 PMID: 28712352

42. Momper S, Dennis MK, Mueller-Williams A. Service Provider Views of Oxycontin Use on an Indian Reservation: Traumatic Effects on the Tribal Community. Families in Society: The Journal of Contemporary Social Services. 2012; 93(4):312–8. https://doi.org/10.1606/1044-3894.4242

43. Rieckmann T, Moore LA, Croy CD, Novins DK, Aarons G. A National Study of American Indian and Alaska Native Substance Abuse Treatment: Provider and Program Characteristics. Journal of Substance Abuse Treatment. 2016; 68:46–56. https://doi.org/10.1016/j.jsat.2016.05.007 PMID: 27431046

44. Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder. 2015; 13(1):23–6. https://doi.org/10.1370/afm.1735 PMID: 25583888

45. Stein BD, Pacula RL, Gordon AJ, Burns RM, Leslie DL, Sorbero MJ, et al. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties. The Milbank Quarterly. 2015; 93(3):561–83. https://doi.org/10.1111/1468-0009.12137 PMID: 26350930